跳至主要内容
临床试验/NCT01423110
NCT01423110已完成2 期

A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BYM338 in Patients With Sporadic Inclusion Body Myositis

Novartis Pharmaceuticals3 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2011年8月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
14
试验地点
3
主要终点
Effect of BYM338 on Thigh Muscle Volume by MRI

研究概览

简要总结

This study will assess the efficacy, safety and tolerability of BYM338 in patients with sporadic Inclusion Body Myositis

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •- Males and Females aged 40-80 with a confirmed diagnosis of sporadic Inclusion Body Myositis

排除标准

  • •Unable to walk at least 3 meters without assistance from another person
  • •Use of oral beta agonists, oral corticosteroids, androgens or androgen inhibitors, or intravenous gamma globulin in the last 6 months
  • •patients with a history or presence of renal impairment and/or liver disease
  • •Other protocol-defined inclusion/exclusion criteria may apply

研究组 & 干预措施

Placebo

Placebo Comparator

干预措施: Placebo (Biological)

BYM338

Experimental

干预措施: BYM338 (Biological)

结局指标

主要结局

Effect of BYM338 on Thigh Muscle Volume by MRI

时间窗: 8 weeks

Change in thigh muscle volume

次要结局

  • Effect of BYM338 on muscle function by 'Timed Get Up and Go' test(8 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验